BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6542045)

  • 1. [Distribution of acetylator phenotypes in the normal Moscow city population and in chronic alcoholism].
    Lil'in ET; Korsunskaia MP; Meksin VA; Drozdov ES; Nazarov VV
    Genetika; 1984 Sep; 20(9):1557-9. PubMed ID: 6542045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Distribution of acetylator phenotypes in the Moscow population].
    Lil'in ET; Korsunskaia MP; Meksin VA; Tarlycheva LV; Shapiro EF
    Genetika; 1983 Aug; 19(8):1378-80. PubMed ID: 6685091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
    Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
    Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
    Singh SP; Pande JN; Khilnani GC; Kailash S
    Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acetylation processes in chronic alcoholics].
    Kovalev IE; Kovalev EN; Seleznev NG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(2):232-4. PubMed ID: 6711211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
    Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
    Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylation phenotyping with sulfamethazine in an Iranian population.
    Sardaş S; Lahijany B; Cok I; Karakaya AE
    Pharmacogenetics; 1993 Jun; 3(3):131-4. PubMed ID: 8334437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation phenotype in colorectal carcinoma.
    Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
    Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylator polymorphism in Alzheimer's disease.
    Ladero JM; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Benítez J
    Eur J Med; 1993 May; 2(5):281-3. PubMed ID: 8252158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylator phenotypes in hyperthyroidism.
    Siegmund W; Franke G; Meng S; Gothe P; Meng W
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):397-9. PubMed ID: 3220615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylation phenotypes in patients with bladder carcinoma.
    Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
    Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
    Goldenkova-Pavlova IV; Bruskin SA; Abdeev RM; Markarova EV; Bigvava SG; Radkevich LA; Kozhekbaeva ZhM; Glotov AS; Gra OA; Zasedatelev AS; Nasedkina TV; Kurdanov KhA; Piruzian ES
    Genetika; 2006 Aug; 42(8):1143-50. PubMed ID: 17025166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylator polymorphism in human colorectal carcinoma.
    Ladero JM; González JF; Benítez J; Vargas E; Fernández MJ; Baki W; Diaz-Rubio M
    Cancer Res; 1991 Apr; 51(8):2098-100. PubMed ID: 2009528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphamethoxazole acetylation in fast and slow acetylators.
    Bozkurt A; Basci NE; Isimer A; Tuncer M; Erdal R; Kayaalp SO
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):164-6. PubMed ID: 2338369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of acetylator polymorphism and its relevance in Papua New Guinea.
    Hombhanje F
    P N G Med J; 1990 Jun; 33(2):107-10. PubMed ID: 2238823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of isoniazid acetylation phenotypes in North Indians.
    Gupta RC; Nair CR; Jindal SK; Malik SK
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.